HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

lascufloxacin

anti-bacterial

Also Known As:

KRP-AM1977

Networked: 8 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        lascufloxacin: 8

Experts

1.	Hayashi, Masahiro: 1 article (08/2021)
2.	Tanaka, Kaori: 1 article (08/2021)
3.	Vu, Hanh: 1 article (08/2021)
4.	Asai, Nobuhiro: 1 article (06/2021)
5.	Hagihara, Mao: 1 article (06/2021)
6.	Kato, Hideo: 1 article (06/2021)
7.	Mikamo, Hiroshige: 1 article (06/2021)
8.	Sakanashi, Daisuke: 1 article (06/2021)
9.	Shibata, Yuichi: 1 article (06/2021)
10.	Suematsu, Hiroyuki: 1 article (06/2021)

Related Diseases

1.	Infections 08/01/2021 - "In this study, minimum inhibitory concentrations (MICs) of lascufloxacin against the reference strains associated with respiratory and head and neck infections. " 01/01/2017 - "These results suggest that lascufloxacin may be useful in treating infections caused by various pathogens, including quinolone-resistant strains."
2.	Coinfection 06/01/2021 - "In conclusion, lascufloxacin resulted in enhanced efficacies against S. pneumoniae and P. intermedia, in both the single and mixed-infection models used. " 06/01/2021 - "In contrast, lascufloxacin showed enhanced antimicrobial activities against S. pneumoniae and P. intermedia in the mixed-infection model. " 06/01/2021 - "This study aimed to evaluate the antimicrobial activity of a new quinolone, lascufloxacin, for the treatment of complicated pneumonia caused by Streptococcus pneumoniae and Prevotella intermedia using a neutropenic mice pneumonia mixed-infection model. " 06/01/2021 - "In vivo pharmacodynamics of lascufloxacin and levofloxacin against Streptococcus pneumoniae and Prevotella intermedia in a pneumonia mixed-infection mouse model."
3.	Pneumonia (Pneumonitis) 06/01/2021 - "These data support the clinical utility of lascufloxacin for use against S. pneumoniae and P. intermedia in the treatment of pneumonia." 06/01/2021 - "This study aimed to evaluate the antimicrobial activity of a new quinolone, lascufloxacin, for the treatment of complicated pneumonia caused by Streptococcus pneumoniae and Prevotella intermedia using a neutropenic mice pneumonia mixed-infection model. " 06/01/2021 - "In vivo pharmacodynamics of lascufloxacin and levofloxacin against Streptococcus pneumoniae and Prevotella intermedia in a pneumonia mixed-infection mouse model."
4.	Healthcare-Associated Pneumonia 02/22/2023 - "Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol."
5.	Severe Acute Respiratory Syndrome 12/01/2020 - "Reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) revealed a positive result, and he was treated with favipiravir, ciclesonide, and lascufloxacin, but he showed poor improvement. "

Related Drugs and Biologics

1.	Quinolones
2.	Levofloxacin (Levaquin)
3.	Member 1 Subfamily B ATP Binding Cassette Transporter
4.	Proteins (Proteins, Gene)
5.	favipiravir
6.	ciclesonide

Related Therapies and Procedures

1.	Therapeutics